Granisetron

Generic Name: Granisetron

Brand Names: Sancuso, Sustol

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₄N_₄O

CAS Number: 109889-09-0

Unique Ingredient Identifier: WZG3J2MCOL

Background: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

Indication: For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).

Associated Conditions: Nausea and vomiting

Associated Therapies: -

Clinical Trials

Comparative Study Between Intravenous Granisetron and Ondansetron on Their Effect on Hemodynamics and Shivering After Spinal Anesthesia in Elective Cesarean Delivery

Not Applicable

Recruiting

Conditions: Hemodynamic Instability and Shivering

Interventions: Drug: ondansetron
Drug: granisetron

First Posted Date: 2024-05-31

Last Posted Date: 2024-05-31

Lead Sponsor: Sohag University

Target Recruit Count: 100

Registration Number: NCT06437236

Locations: 🇪🇬
Sohag university Hospital, Sohag, Egypt

Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery

Phase 4

Not yet recruiting

Conditions: Postoperative Nausea
Vomiting

Interventions: Drug: Aprepitant
Drug: Granisetron

First Posted Date: 2022-11-30

Last Posted Date: 2022-11-30

Lead Sponsor: Baskent University

Target Recruit Count: 60

Registration Number: NCT05632224

Locations: 🇹🇷
Baskent University Ankara Hospital, Ankara, Turkey

Safety Study of Repeat Doses of SUSTOL in Adults

Phase 4

Active, not recruiting

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions: Drug: SUSTOL

First Posted Date: 2022-06-28

Last Posted Date: 2023-07-28

Lead Sponsor: Heron Therapeutics

Target Recruit Count: 300

Registration Number: NCT05434663

Locations: 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States

Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery

Phase 3

Completed

Conditions: Vomiting, Postoperative
Perioperative Complication
Nausea
Bariatric Surgery Candidate
Drug Effect

Interventions: Drug: Metoclopramide and Ondanteron
Drug: Granisetron
Drug: Metoclopramide
Drug: Ondansetron

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-29

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 130

Registration Number: NCT05087615

Locations: 🇮🇷
Loghman Hakim Hospital, Tehran, Iran, Islamic Republic of

A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA

Phase 3

Completed

Conditions: 1mg Vs 3 mg of Granisetron

Interventions: Drug: Granisetron

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-21

Lead Sponsor: Cairo University

Target Recruit Count: 210

Registration Number: NCT04918862

Locations: 🇪🇬
Ahmed Abdalla Mohamed, Cairo, Egypt

Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy

Phase 4

Conditions: Nausea and Vomiting, Postoperative

Interventions: Drug: Granisetron

First Posted Date: 2021-05-25

Last Posted Date: 2021-05-25

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT04899817

Locations: 🇪🇬
Assiut university hospital, Assiut, Egypt

The Effect of Intravenous Granisetron and Ondansetron in Patients Undergoing Cesarean Section

Phase 3

Completed

Conditions: Vomiting, Postoperative
Postoperative Complications
Hypotension

Interventions: Drug: ondansetron
Drug: Granisetron
Drug: Saline

First Posted Date: 2020-11-03

Last Posted Date: 2020-11-03

Lead Sponsor: Ataturk University

Target Recruit Count: 120

Registration Number: NCT04613726

Locations: 🇹🇷
Mehmet AKSOY, Erzurum, string:Turkey, Turkey

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

Phase 2

Withdrawn

Conditions: Gastroparesis

Interventions: Drug: Granisetron

First Posted Date: 2020-08-06

Last Posted Date: 2022-02-14

Lead Sponsor: Indiana University

Registration Number: NCT04501211

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States

Cisplatin Disposition and Kidney Injury

Phase 3

Active, not recruiting

Conditions: Nephrotoxicity

Interventions: Drug: Granisetron
Drug: Ondansetron
Drug: Palonosetron

First Posted Date: 2019-01-28

Last Posted Date: 2024-11-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 72

Registration Number: NCT03817970

Locations: 🇺🇸
UCHealth-Metro Denver, Denver, Colorado, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Pharmacogenomics and Post-Operative Nausea and Vomiting

Phase 4

Completed

Conditions: Postoperative Nausea

Interventions: Drug: Granisetron
Drug: Ondansetron

First Posted Date: 2018-04-19

Last Posted Date: 2020-10-28

Lead Sponsor: Mayo Clinic

Target Recruit Count: 92

Registration Number: NCT03503292

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy